Capital Investment Counsel Inc Raises Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Capital Investment Counsel Inc grew its stake in Hologic, Inc. (NASDAQ:HOLX) by 3.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,724 shares of the medical equipment provider’s stock after buying an additional 200 shares during the quarter. Capital Investment Counsel Inc’s holdings in Hologic were worth $413,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC boosted its stake in shares of Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after acquiring an additional 2,174,093 shares during the period. Nordea Investment Management AB boosted its stake in shares of Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after acquiring an additional 544,889 shares during the period. Swedbank AB boosted its stake in shares of Hologic by 18.8% in the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after acquiring an additional 306,562 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Hologic by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock worth $110,700,000 after acquiring an additional 238,222 shares during the period. Finally, Barclays PLC boosted its stake in shares of Hologic by 47.6% in the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock worth $58,507,000 after acquiring an additional 231,578 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insiders Place Their Bets

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.88% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on HOLX. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a research note on Monday, February 3rd. Mizuho dropped their price target on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. BNP Paribas raised Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Leerink Partnrs lowered Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Finally, Jefferies Financial Group began coverage on Hologic in a research note on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target for the company. Ten analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Hologic presently has an average rating of “Moderate Buy” and a consensus price target of $85.77.

Hologic Trading Up 0.2 %

Shares of NASDAQ HOLX opened at $64.32 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The business’s 50 day moving average price is $70.09 and its 200-day moving average price is $76.74. Hologic, Inc. has a fifty-two week low of $62.69 and a fifty-two week high of $84.67. The company has a market cap of $14.43 billion, a price-to-earnings ratio of 20.29, a PEG ratio of 2.12 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.